Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer-Reference-Cited by-同舟云学术

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer

Published:2017-07 Issue:1 Volume:72 Page:34-42
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Annala Matti,Struss Werner J.,Warner Evan W.,Beja Kevin,Vandekerkhove Gillian,Wong Amanda,Khalaf Daniel,Seppälä Irma-Liisa,So Alan,Lo Gregory,Aggarwal Rahul,Small Eric J.,Nykter Matti,Gleave Martin E.,Chi Kim N.,Wyatt Alexander W.

Publisher

Elsevier BV

Subject

Urology

Reference29 articles.

1. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands;Goldgar;J Natl Cancer Inst,1994

2. Familial risk and heritability of cancer among twins in Nordic countries;Mucci;JAMA,2016

3. Integrative clinical genomics of advanced prostate cancer;Robinson;Cell,2015

4. Inherited DNA-repair gene mutations in men with metastatic prostate cancer;Pritchard;N Engl J Med,2016

5. The molecular taxonomy of primary prostate cancer;Cancer Genome Atlas Research Network;Cell,2015

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC);Urologic Oncology: Seminars and Original Investigations;2024-10

2. Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent -rate method ideal for real-world analyses;eBioMedicine;2024-09

3. Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race;ClinicoEconomics and Outcomes Research;2024-09

4. Cancer de prostate métastatique résistant à la castration et inhibiteurs de PARP : de la génomique tumorale aux nouvelles associations thérapeutiques;Bulletin du Cancer;2024-09

5. Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real‐world setting of metastatic prostate cancer;BJU International;2024-07-10